Concept
Kidney Monitoring
Future of Cancer Science | AACR Cancer Progress Report 2025 / Detecting Minimal Residual Disease and Recurrence
"Similarly, in metastatic kidney cancer, researchers showed that tracking ctDNA over time can offer important insights for patients receiving standard immunotherapy or targeted drugs. They found that patients whose ctDNA remained undetectable had much longer periods without disease progression, while those with detectable ctDNA were more likely to experience relapse, revealing its potential to monitor remission and relapse in real time (1088)Basu A, et al. (2024) JCO Precis Oncol, 8: e2400667.."
Related Ideas
- Immune ResponseFuture of Cancer Science | AACR Cancer Progress Report 2025 · Monitoring Treatment Response and Predicting Resistance
- Dynamic CtdnaFuture of Cancer Science | AACR Cancer Progress Report 2025 · Monitoring Treatment Response and Predicting Resistance
- KRAS ProfilingFuture of Cancer Science | AACR Cancer Progress Report 2025 · Monitoring Treatment Response and Predicting Resistance
- Clinical BarriersFuture of Cancer Science | AACR Cancer Progress Report 2025 · Detecting Minimal Residual Disease and Recurrence
- Risk StratificationFuture of Cancer Science | AACR Cancer Progress Report 2025 · Diagnosing Cancer and Predicting Metastases
- Early DiagnosisFuture of Cancer Science | AACR Cancer Progress Report 2025 · Diagnosing Cancer and Predicting Metastases
- Neoantigen VaccinesFuture of Cancer Science | AACR Cancer Progress Report 2025 · Cancer Vaccines